These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 13120873)

  • 21. The effects of folic or folinic acid on the toxicity of 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(3,4-dichlorobenzyloxy)-1,3,5-triazine hydrochloride, an antifolate, in dogs.
    Lee CC; Heiffer MH; Kintner LD
    Toxicol Appl Pharmacol; 1976 Oct; 38(1):29-37. PubMed ID: 1086534
    [No Abstract]   [Full Text] [Related]  

  • 22. Inhibition of chicken liver 5-aminoimidazole-4-carboxamide ribonucleotide transformylase by 5,8-dideaza analogues of folic acid.
    Mueller WT; Smith GK; Benkovic SJ; Hynes JB
    Biochem Pharmacol; 1988 Feb; 37(3):449-51. PubMed ID: 3337744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analogues of folic acid and the activity of dihydrofolic acids in the synthesis of methionine by Escherichia coli.
    GUEST JR; WOODS DD
    Biochem J; 1962 Jan; 82(1):26-35. PubMed ID: 13902735
    [No Abstract]   [Full Text] [Related]  

  • 24. Effects of folinic acid on amethopterin-induced inhibition of the Ehrlich ascites carcinoma.
    SARTORELLI AC; UPCHURCH HF; BOOTH BA
    Cancer Res; 1962 Jan; 22():102-6. PubMed ID: 14497283
    [No Abstract]   [Full Text] [Related]  

  • 25. Irreversible enzyme inhibitors. CV. Differential irreversible inhibition of vertebrate dihydrofolic reductases by derivatives of 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-s-triazines substituted with a terminal sulfonyl fluoride.
    Baker BR; Lourens GJ
    J Med Chem; 1967 Nov; 10(6):1113-22. PubMed ID: 6056040
    [No Abstract]   [Full Text] [Related]  

  • 26. Plasmodium knowlesi: in vitro evaluation of antimalarial activity of folic acid inhibitors.
    McCormick GJ; Canfield CJ; Willet GP
    Exp Parasitol; 1971 Aug; 30(1):88-93. PubMed ID: 5316583
    [No Abstract]   [Full Text] [Related]  

  • 27. Syntheses and antifolate activity of 5-methyl-5-deaza analogues of aminopterin, methotrexate, folic acid, and N10-methylfolic acid.
    Piper JR; McCaleb GS; Montgomery JA; Kisliuk RL; Gaumont Y; Sirotnak FM
    J Med Chem; 1986 Jun; 29(6):1080-7. PubMed ID: 2423690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single system for measuring growth responses of three organisms to folacin and related factors (bacterimetric studies. VII.).
    TOENNIES G; FRANK HG; GALLANT DL
    Growth; 1952 Dec; 16(4):. PubMed ID: 13021576
    [No Abstract]   [Full Text] [Related]  

  • 29. The incorporation of formate-C14 into citrovorum factor.
    ZAKRZEWSKI SF; NICHOL CA
    J Biol Chem; 1955 Apr; 213(2):697-704. PubMed ID: 14367330
    [No Abstract]   [Full Text] [Related]  

  • 30. Irreversible enzyme inhibitors. 168. Irreversible inhibition of dihydrofolate reductase and cell wall transport by pyrimidines and dihydro-s-triazines with pyridinium side chains.
    Baker BR; Vermeulen NM; Ryan AJ
    J Med Chem; 1970 Mar; 13(2):280-4. PubMed ID: 5418502
    [No Abstract]   [Full Text] [Related]  

  • 31. Increase of urinary citrovorum factor activity in patients receiving methotrexate (amethopterin).
    LI MC; NIXON WE; FREEMAN MV
    Proc Soc Exp Biol Med; 1958 Jan; 97(1):29-32. PubMed ID: 13518171
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmacokinetics of Aryldihydro-s-triazines with antifolate activity II: Blood levels and their relevance to antineoplastic activity in rats.
    Upton RA; Ashley JJ; Ryan AJ
    J Pharm Sci; 1978 Mar; 67(3):310-4. PubMed ID: 641713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimetabolite-metabolite combination cancer chemotherapy. Effects of intraarterial methotrexate-intramuscular Citrovorum factor therapy in human cancer.
    SULLIVAN RD; MILLER E; SIKES MP
    Cancer; 1959; 12():1248-62. PubMed ID: 13835650
    [No Abstract]   [Full Text] [Related]  

  • 34. The synthesis of serine and Leuconostoc citrovorum factor by cell suspensions of Streptococcus faecalis R.
    LASCELLES J; WOODS DD
    Biochem J; 1954 Nov; 58(3):486-97. PubMed ID: 13208641
    [No Abstract]   [Full Text] [Related]  

  • 35. Antimetabolite-metabolite cancer chemotherapy using continuous intra-arterial methotrexate with intermittent intramuscular citrovorum factor. Method of therapy.
    DUFF JK; SULLIVAN RD; MILLER E; ULM AH; CLARKSON BD; CLIFFORD P
    Cancer; 1961; 14():744-52. PubMed ID: 13724783
    [No Abstract]   [Full Text] [Related]  

  • 36. Studies on the biological interrelationships of folic acid, citrovorum factor, and the antimetabolite, aminopterin.
    GOLDIN A; GREENSPAN EM; VENDITTI JM; SCHOENBACH EB
    J Natl Cancer Inst; 1952 Apr; 12(5):987-1002. PubMed ID: 14928052
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of the teratogenic folic acid antagonist, 9-methyl pteroylglutamic acid, on hydroxyproline levels in fetal rat limbs.
    Schmidt RR; Chepenik KP; Paynton BV
    J Embryol Exp Morphol; 1977 Oct; 41():289-94. PubMed ID: 591876
    [No Abstract]   [Full Text] [Related]  

  • 38. Instability of compounds in the folic acid series.
    JUKES TH
    Science; 1954 Aug; 120(3112):324. PubMed ID: 13186851
    [No Abstract]   [Full Text] [Related]  

  • 39. Combined distance geometry analysis of dihydrofolate reductase inhibition by quinazolines and triazines.
    Ghose AK; Crippen GM
    J Med Chem; 1983 Jul; 26(7):996-1010. PubMed ID: 6864738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experiments on the biological activities of various fractions of the folic acid antagonist "X-methyl" folic acid.
    Stokstad EL; Okinaka O; Kusano G
    Arch Biochem Biophys; 1986 Nov; 251(1):260-5. PubMed ID: 3789733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.